BioVentrix Announces Study Design for REVIVE-HF: Randomized Controlled Trial (RCT) in EuropeSep 23, 2019
BioVentrix Achieves 2019 NUB Reimbursement Status 1 in Germany for Revivent TC™ TransCatheter Ventricular Enhancement SystemFeb 28, 2019
BioVentrix Announces Raymond W. Cohen as Chairman of the Board and Newly Appointed Accredited Public Company Directors, Rinda K. Sama and Andrew G. Hinson to its Board of DirectorsJul 21, 2021
BioVentrix Receives 2021 NUB Status 1 Reimbursement Renewal in Germany for the Revivent TC™ TransCatheter Ventricular Enhancement SystemFeb 8, 2021